Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
ADNOC Gas Targets Up to $4B Profit in 2026 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
A US district court upheld the validity of Novartis' patent for its top-selling multiple sclerosis (MS) drug Gilenya, rejecting a lawsuit from generic drug maker HEC.
Gilenya is the Swiss drugmaker's No. 2 revenue generator at $738 million in the second quarter.
HEC had sought approval to make a generic copy of Gilenya before the expiration of Novartis' patent with the US Food and Drug Administration (FDA).
The Swiss drugmaker said it continued the injunction against the marketing and sale of Gilenya and other generics granted to it in June 2019.
The FDA approved three generic versions of the Novartis MS treatment in December.
Novartis had settlement agreements with other manufacturers to allow them to launch generic versions of Gilenya before the patent expires in 2027.
